2009
DOI: 10.1016/j.nurt.2009.08.001
|View full text |Cite
|
Sign up to set email alerts
|

Sodium Channel Blockers for the Treatment of Neuropathic Pain

Abstract: Summary:Drugs that block voltage-gated sodium channels are efficacious in the management of neuropathic pain. Accordingly, this class of ion channels has been a major focus of analgesic research both in academia and in the pharmaceutical/biotechnology industry. In this article, we review the history of the use of sodium channel blockers, describe the current status of sodium channel drug discovery, highlight the challenges and hurdles to attain sodium channel subtype selectivity, and review the potential usefu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
32
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 60 publications
(32 citation statements)
references
References 200 publications
(143 reference statements)
0
32
0
Order By: Relevance
“…In support, functional knockdown of Na v 1.8 in rats or deletion of the Na v 1.8 gene reduces hyperalgesia and allodynia in neuropathic pain models (Dib-Hajj et al, 2010;Lampert et al, 2010). Likewise, systemic and spinal administrations of Na v 1.8 channel blockers partially reverse pain-related behaviors in preclinical animal models of chronic pain (Bear et al, 2009;Bhattacharya et al, 2009;Matulenko et al, 2009;Priest, 2009). Although Na v 1.8 antagonists may have analgesic efficacy in patients coping with chronic pain, the high degree of structural homology within the VGSC family and side effects of existing blockers have limited their clinical use (England, 2008;Dworkin et al, 2010).…”
Section: Discussionmentioning
confidence: 98%
“…In support, functional knockdown of Na v 1.8 in rats or deletion of the Na v 1.8 gene reduces hyperalgesia and allodynia in neuropathic pain models (Dib-Hajj et al, 2010;Lampert et al, 2010). Likewise, systemic and spinal administrations of Na v 1.8 channel blockers partially reverse pain-related behaviors in preclinical animal models of chronic pain (Bear et al, 2009;Bhattacharya et al, 2009;Matulenko et al, 2009;Priest, 2009). Although Na v 1.8 antagonists may have analgesic efficacy in patients coping with chronic pain, the high degree of structural homology within the VGSC family and side effects of existing blockers have limited their clinical use (England, 2008;Dworkin et al, 2010).…”
Section: Discussionmentioning
confidence: 98%
“…Current analgesics include those that act locally (e.g., lidocaine) or attenuate neurotransmitter release through inhibition of ion channels (voltage-sensitive Ca 2+ , Na + , or K + channels) in central nerve pathways. Anticonvulsant and anesthetic sodium channel blockers have long been used to treat acute or chronic pain, such as trigeminal neuralgia, by reducing the generation of action potentials and nerve excitation (Bhattacharya et al, 2009). For peripheral pain, nonsteroidal anti-inflammatory drugs have mild 60 Veldhuis et al analgesic, anti-inflammatory, and antipyretic properties that inhibit production of algesic prostaglandins and are effective for inflammatory conditions such as arthritis (Andersson et al, 2011).…”
Section: A the Need For Alternative Therapeuticsmentioning
confidence: 99%
“…Both are central to human neuromuscular, cardiovascular, and neural physiology. Consequently, they are targets for a host of pharmaceuticals used to treat a diverse set of disorders and remain active targets for drug development (5)(6)(7). Recently, single subunit, six-transmembrane segment Na V s have been identified in a large number of bacteria from diverse environments (8,9).…”
mentioning
confidence: 99%